Navigation Links
Kibow Biotech Marks Its Continued Growth with Relocation to Larger Facilities

NEWTOWN SQUARE, Pa., July 31, 2012 /PRNewswire/ -- Kibow Biotech Inc. (KIBOW) is pleased to announce its recent relocation to a custom-built probiotic R&D center dedicated to the development and commercialization of natural formulations (mainly targeting renal failure). The new 7500 sq. ft. center is located at 4781 West Chester Pike, very close to the Company's previous operations at 4629 West Chester Pike in the same Newtown Square, PA area. For Kibow, the custom-built R&D facility and new office space means expanded research operations and also improved client service, new amenities for employees and room for growth.

The facility includes 2500 sq. feet of R&D lab space divided into six separate labs with a large office work area for the lab staff. Each lab is fully equipped with the necessary operational equipment, instruments and safety facilities in compliance with local, state and federal regulations, as well as with the Occupational Safety Hazard Authority (OSHA) ordinances. The rest of the 5000 sq. ft. area is comprised of six corporate management offices, several well-designed cubicles for sales, marketing and customer service staff, a state-of-the-art web and teleconference & lunch room and a combined cold room and shipping facilities.

"As a consequence of the positive market reaction to our recent introduction of Renadyl™ ( for kidney compromised patients, and in view of the continued success of Azodyl™, our animal formulation under world-wide license to Vetoquinol, SA (, we needed to expand. We were fortunate to find an appropriate space so close to our previous office. We really wanted to limit the impact that relocation could have on our clients and our employees. I don't think we could have found a better location for our team. Our new location and enhanced operational efficiencies will help us continue to grow and evolve to keep pace with our customers' needs, allowing us to provide exceptional value and superior service along the way," said Dr. Natarajan Ranganathan - the Managing Director.

Our new address will be: 4781 West Chester Pike, Newtown Square, PA 19073. All of Kibow's phone numbers and fax numbers will remain the same.

About Kibow Biotech: Founded in 1997, Kibow Biotech specializes in research and development of probiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company.

Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in the current limited human trials or that data from patients enrolled in the study may not be useful or conclusive or sufficient to guide future development of Renadyl™. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop dietary supplements using the technologies of the Company, risks associated with completing clinical trials of product candidates, the possibility that clinical testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

For further information, contact:

Natarajan Ranganathan, Ph.D., Managing Director (R&D)
1 (610) 353 5130

This press release was issued through eReleases® Press Release Distribution. For more information, visit  

SOURCE Kibow Biotech Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GenWay Biotech Appoints New Vice President of Custom/OEM
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
6. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
7. Obamacare Ruling, Other Pivotal News Rocks Biotech Sector in June
8. Tougher Times May be Ahead for Biotechs: 1H12 Fundraising Slows
9. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... -- --> --> ... das Patent über eine neue Hepatitis-B-Behandlung, welches sie gemeinsam ... Enyo Pharma vergeben haben. Im Rahmen ... von Edelris gemeinsam mit seinen Partnern Inserm und Poxel ... identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die zu ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David ... 130884WC. , According to court documents, Adcock testified that on May 10, 2010 he ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Beddit® has launched ... Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that rates ... how well you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development and ... of its current state of the art research, development and manufacturing facility outside ... its manufacturing capacity as well as to support its clients’ growing research and ...
(Date:11/25/2015)... ... 2015 , ... Since its launch in 2012, the Regenestem ... cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent ... (RTM). , Organizations are required to hold a registered trademark in order to ...
Breaking Medicine News(10 mins):